THIRD QUARTER, JULY-SEPTEMBER 2023
- Net sales amounted to MSEK 0.0 (0.0)
- Operating loss (EBIT) amounted to MSEK -5.6 (-4.5)
- Net loss amounted to MSEK -5.5 (-4.5)
- Net cash flow amounted to MSEK -4.6 (-7.4)
- EPS before and after dilution amounted to SEK -0.06 (-0.17)
JANUARY- SEPTEMBER 2023
- Net sales amounted to MSEK 0.0 (0.0)
- Operating loss (EBIT) amounted to MSEK -17.8 (-20.5)
- Net loss amounted to MSEK -18.3 (-20.5)
- Net cash flow amounted to MSEK 7.7 (-9.1)
- EPS before and after dilution amounted to SEK -0.32 (-0.87)
Significant events
During the reporting period
- In August, Emplicure hired Johan Magné as Sales Director with a long background in Swedish Match to drive the company's sales of smååTM.
- In September, the company received a research grant of MSEK 1.0 from Vinnova, Sweden's Innovation Authority, within the framework of the competence center SweDeliver.
- Also in September, the company announced that the company, through its subsidiary Amplicon, initiates a collaboration on a clinical study with CTC Clinical Trial Consultants AB, a recognized contract research organization (CRO).
After the reporting period
- In October the company was informed that a buyout consortium had agreed to acquire over 90 per cent of the shares in Emplicure and intends to initiate squeeze-out proceedings.
- In November Emplicure announced the hiring of a marketing manager, Sophia Bailey
- In November the buyout consortium initiated squeeze-out proceedings and Emplicure applied for delisting. Nasdaq approved the delisting with the 27 November as the last trading day